Greg MulhollandTo ask the Secretary of State for Health, what support his Department gives to children with tuberous sclerosis complex.

George Freeman

The commissioning of most health services for children is the responsibility of local clinical commissioning groups. NHS England has the role of commissioning the specialised services which patients with tuberous sclerosis access. In addition clinical policies are developed for new treatments that potentially change the impact of the disease.

Mr Roger GodsiffTo ask the Secretary of State for Health, pursuant to the Answer of 8 March 2016 to Question 29649, how patients whose clinical commissioning group has decided not to fund the provision of Sativex can access that medication.

George Freeman

Where a treatment is not routinely funded by a clinical commissioning group (CCG), the CCG is required to have systems in place to consider individual funding requests from clinicians who believe their patient would benefit from that treatment due to their clinical exceptionality.

Mr Roger GodsiffTo ask the Secretary of State for Health, whether clinical commissioning groups are permitted to prescribe medications which NICE does not recommend as cost effective.

George Freeman

The National Institute for Health and Care Excellence’s (NICE) clinical guidelines represent best practice, based on the available evidence, and are developed through wide consultation. They relate to a whole pathway of care and are not subject to the same legal funding requirement as NICE’s technology appraisals.

Mr Roger GodsiffTo ask the Secretary of State for Health, what the difference is between NICE's clinical guidelines and its positive guidance; and what steps his Department is taking to make healthcare commissioners aware of when they may prescribe outside guidelines.

Mr Stewart JacksonTo ask the Secretary of State for Health, what legal costs have been incurred by NHS England in respect of the use of the NHS logo by the Vote Leave group; and if he will make a statement.

Tulip SiddiqTo ask the Secretary of State for Health, with reference to his Department's press release of 25 November 2015, entitled Department of Health's settlement at the Spending Review 2015, how the figure of £2 billion of asset sales over five years was calculated; what the 25 potential asset sales with the highest prospective value are; what the value of projected asset sales scheduled to take place will be in each of the next five years; and if he will make a statement.

Paul FlynnTo ask the Secretary of State for Health, how many instances of adverse reactions have been reported under the Yellow Card Scheme; and what the nature of the reaction reported was in the case of (a) dabigatran, (b) rivaroxaban and (c) apixaban.

Mr Roger GodsiffTo ask the Secretary of State for Health, what steps his Department is taking to make the drug Everolimus available for the treatment of patients with tuberous sclerosis; and when that drug will be available on the NHS.

George Freeman

The Clinical Priorities Advisory Group recommendation relating to the clinical policy statement for using Everolimus to treat Angiomyolipomas was discussed at the Specialised Commissioning Oversight Group meeting on 9 March. The outcome of this meeting will be shared as soon as it is available.

Catherine McKinnellTo ask the Secretary of State for Health, with reference to the Answer of 21 September 2015 to Question HL2285, what progress Public Health England has made on making the Systemic Anticancer Therapy dataset publicly available; what the timetable is for that dataset being fully accessible; and whether he plans that the dataset will be used to collect data on patient outcomes for treatment funded through the new Cancer Drugs Fund.